Corrigendum to "Impact of simultaneous administration on immune responses to vaccines routinely recommended for use during pregnancy

Abstract

Maternal immunization is a well-established public health tool for protecting pregnant people and their infants from morbidity and mortality due to infectious diseases. Optimal timing for administration of routinely recommended vaccines in pregnancy varies by product and considers whether the pathogen is seasonal and whether the benefit of vaccination is primarily intended for the infant, the pregnant person, or both. As additional vaccines are recommended for antenatal use, the programmatic benefits of simultaneous administration are clear: reducing missed opportunities for vaccination, improving vaccine coverage, and minimizing the healthcare and personal burdens of additional visits. However, there is a paucity of data evaluating immune responses to vaccination when multiple vaccines are simultaneously administered in pregnancy. In this review, we summarize existing data on the impact of simultaneous administration of vaccines routinely used in pregnancy and expand the evidence base by including comparisons of singular or sequential administration strategies. Of 35 reviewed studies, most evaluated the simultaneous administration of influenza and COVID-19 vaccines (n = 13) or Tdap and meningococcal conjugate vaccines (n = 9); only four studies evaluated RSV vaccines. Fourteen (40%) indicated antibody responses were similar when vaccines routinely recommended in pregnancy were given simultaneously compared to alone or sequentially; of the 21 that indicated some antibody responses may be lower, the vaccine components most often impacted were pertussis, as reported in 11 studies. The clinical relevance of these relative reductions is not known, and we discuss these-and other key data gaps-as well as areas where further research is needed.